Nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
In the 12th century BCE, many Israelite settlements appeared in the central hill country of Canaan, which was formerly an open terrain. These settlements lacked evidence of pork consumption, compared to Philistine settlements, had four-room houses and lived by an egalitarian ethos, which was exemplified by the absence of elaborate tombs, governor's mansions, certain houses being bigger than others etc. They followed a mixed economy, which prioritized self-sufficiency, cultivation of crops, animal husbandry and small-scale craft production. New technologies such as terraced farming, silos for grain storage and cisterns for rainwater collection were simultaneously introduced. These settlements were built by inhabitants of the "general Southland" (i.e. modern Sinai and the southern parts of Israel and Jordan), who abandoned their pastoral-nomadic ways. Canaanites who lived outside the central hill country were tenuously identified as Danites, Asherites, Zebulunites, Issacharites, Naphtalites and Gadites. These inhabitants do not have a significant history of migration besides the Danites, who allegedly originate from the Sea Peoples, particularly the Dan(an)u. Nonetheless, they intermingled with the former nomads, due to socioeconomic and military factors. Their interest in Yahwism and its concern for the underprivileged was another factor. Possible allusions to this historical reality in the Hebrew Bible include the aforementioned tribes, except for Issachar and Zebulun, descending from Bilhah and Zilpah, who were viewed as "secondary additions" to Israel.
The partisan section took care of the armed defense of the territory, women assisted men with provisions, and party cadres had to keep in touch with the party federation. The revolutionaries established a “People's Tribunal,” which was based in the town square and had the power to try “enemies of the people". An internment camp held many agrarians and notables. The revolutionary experience worried both conservatives and communist leaders, who pressed Cavallaro to calm tempers and end the revolution. The mayor became spokesman for the rebels and convinced most of them to return home and lay down their arms. Diehards refused and went into hiding. Finally, on March 9, the prefect of Reggio Calabria sent departments of carabinieri and police to Caulonia. They arrested 365 men, who were referred to the Locri court for constitution of an armed gang, murder, violence to private individuals and usurpation of public office. On April 15, Cavallaro resigned as mayor. British historian Jonathan Dunnage reported an "institutional continuity" of the civil servants who survived these regime changes Civil servants were not purged either after 1922 or 1943. The "institutional continuity" of the bureaucracy of Calabria were committed to preserving the social structure. On 2 June 1946 Calabria, like the rest of the Mezzogiorno, voted solidly to retain the monarchy. The traditional political system in Calabria continued after 1945. During the war, the already low living standards of Calabria declined further and the region was notorious as one of Italy's most violent areas.
In a joint statement on 13 January 2026, the prime ministers of Greenland and Denmark said that Greenland was facing an "unacceptable pressure" campaign and a "geopolitical crisis" caused by the US. They said that Greenland is not for sale under any circumstances. Frederiksen said, "our message is clear: Greenland is not for sale" and "you can't buy another people". Nielsen emphasised that talk about buying another people shows a lack of respect, and that Greenland does not want to be owned nor governed by the US. Greenlandic politicians have welcomed a NATO mission in Greenland to protect the island following Trump's threats.
Sources: en.wikipedia.org
AlphaFold 2 scoring more than 90 in CASP's global distance test (GDT) was considered a great achievement in computational biology. Nobel Prize winner and structural biologist Venki Ramakrishnan called the result "a stunning advance on the protein folding problem", adding that "It has occurred decades before many people in the field would have predicted. It will be exciting to see the many ways in which it will fundamentally change biological research." AlphaFold 2's success received wide media attention. News pieces appeared in the science press, such as Nature, Science, MIT Technology Review, and New Scientist, and the story was covered by national newspapers. A frequent theme was the ability to predict protein structures based on the constituent amino acid sequence, expected to have benefits in the life sciences—accelerating drug discovery and enabling better understanding of diseases. Some have noted that even a perfect answer to the protein prediction problem still leaves questions about the protein folding problem (and thus protein dynamics)—understanding in detail how the folding process actually occurs in nature (and how sometimes they can also misfold).
SNX8 is thought to be an adaptor protein involved in the endosome-to-Golgi transport pathway, participating in endocytosis and endosomal sorting and signaling. It downregulates retrograde transport of intracellular proteins from the early endosome compartment to the trans-Golgi network in a retromer-mediated manner. SNX8 is therefore localized in early endosomes, as its colocalization with components of the retromer such as SNX1, SNX2, Vps26 and Vps35 has been demonstrated by some studies (and also with EEA1). Furthermore, the dynamics of endosomal structures with SNX8-enriched membrane domains are regulated by the opposite motor proteins dynein-1 containing LIC1 and kinesin-1, both of which allow SNX8-mediated cargo movement through the cytosol by exerting forces on these structures. The biological functions of SNX8 that have been studied, all of which involve its role in intracellular endosomal transport, are explained in more detail in the following sections.
The purpose of radiological emergency preparedness is to protect people from the effects of radiation exposure after a nuclear accident or bomb. Evacuation is the most effective protective measure. However, if evacuation is impossible or even uncertain, then local fallout shelters and other measures provide the best protection.
Sources: en.wikipedia.org
== Clinical trials == The drug is currently under development by AbbVie. Navitoclax is used as mono-therapy as well as in combination with chemotherapies (paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies (in both pediatric and adult patients) and solid tumors including ovarian cancer, breast cancer, lung cancer. Additionally, an ongoing global multi-center, randomized, open-label, phase 3 study evaluating efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in adult patients with relapsed/refractory myelofibrosis was initiated on 31 August 2020. The study is expected to conclude in 2026.
== Consumerism == Historians debate whether the spread of American-style consumerism to Western Europe (and Japan) was part of the Cold War. Steigerwald reviews the debate by looking at the book Trams or Tailfins? Public and Private Prosperity in Postwar West Germany and the United States (2012) by Jan L. Logemann:
In July, the chief administrator of the Environmental Protection Agency announced rescinding of the 2009 endangerment finding, which concluded that planet-warming greenhouse gases pose a threat to public health. (The endangerment finding is the scientific determination that underpins the federal government's legal authority to combat climate change.) In concurrence with the attempt to rollback the endangerment finding, Trump's Department of Energy released an assessment titled A Critical Review of Impacts of Greenhouse Gas Emissions on the U.S. Climate. The report was assembled by five climate science contrarians and was heavily criticized for cherry-picked evidence, falsehoods, and distortions. The Union of Concerned Scientists called it "deeply flawed [and] anti-science". Climate scientist Andrew Dessler called it "a mockery of science". On February 12, 2026, the EPA formally rescinded the Endangerment Finding. In August 2025, the Bureau of Land Management initiated a review of offshore wind energy regulations and revised its rules to favor fossil fuel production over renewables. On September 23, 2025, Trump told the United Nations General Assembly that climate change is "the greatest con job ever perpetrated on the world", that scientific predictions "were made by stupid people", and that renewable energy is a "scam". In October 2025, the Department of Energy cancelled 321 clean energy grants, totaling $7.56 billion, issued in the Biden administration.
== History == The NIH Intramural Research Program (IRP) traces its roots to 1887, when a one-room laboratory on Staten Island was created within the Marine Hospital Service, a predecessor agency to the U.S. Public Health Service. This laboratory evolved into the Hygienic Laboratory, which moved to Washington, D.C., in 1891 and, with the Ransdell Act of 1930, became the National Institute of Health. Several of the IRP's initial Institutes were established over the next two decades and, after World War II, Vannevar Bush, director of the Office of Scientific Research and Development, outlined a program for postwar scientific research that affirmed the contributions of "remote and unexpected fields of medicine and the underlying sciences" in the progress against disease and the benefits of cooperative endeavors with industry and academia. The disease orientation and categorical structure of the IRP had its genesis in the establishment of the National Cancer Institute (NCI) in 1944. In 1948, Congress passed the National Heart Act, which created the National Heart Institute, and soon after established institutes for research on mental health, oral diseases, neurological problems, and blindness. Today, the IRP consists of individual programs housed in 23 of the NIH Institutes and Centers, creating a network of multi-disciplinary, federally funded laboratories with an emphasis on translational research.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.